MedTrace Logo

Expanded Access to Venetoclax

NCT03123029 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-01-30

No results posted yet for this study

Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Conditions

  • Acute Myeloid Leukemia (AML)
  • Chronic Lymphocytic Leukemia (CLL)
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • Acute Lymphoblastic Leukemia (ALL)
  • Amyloidosis
  • Plasma Cell Leukemia

Interventions

DRUG

Venetoclax

Venetoclax will be administered orally.

Sponsors & Collaborators

Principal Investigators

  • ABBVIE INC. · AbbVie

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03123029 on ClinicalTrials.gov